Cipher Pharmaceuticals (TSE:CPH) Share Price Passes Above 50 Day Moving Average – What’s Next?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR)’s stock price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of C$15.77 and traded as high as C$18.36. Cipher Pharmaceuticals shares last traded at C$17.89, with a volume of 50,900 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on CPH shares. Stifel Nicolaus boosted their target price on shares of Cipher Pharmaceuticals from C$16.00 to C$17.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Stifel Canada upgraded shares of Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 12th. Finally, Leede Financial downgraded shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 13th.

Cipher Pharmaceuticals Trading Up 1.5 %

The company has a current ratio of 11.18, a quick ratio of 2.67 and a debt-to-equity ratio of 0.33. The business has a 50 day moving average of C$15.77 and a two-hundred day moving average of C$11.24. The firm has a market cap of C$457.81 million, a P/E ratio of 14.66 and a beta of 1.25.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its quarterly earnings data on Thursday, August 8th. The company reported C$0.16 earnings per share for the quarter, beating the consensus estimate of C$0.15 by C$0.01. The company had revenue of C$7.26 million for the quarter, compared to analyst estimates of C$7.52 million. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. Analysts predict that Cipher Pharmaceuticals Inc. will post 1.5059761 earnings per share for the current year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.